N@N

MedaSorb Technologies Corporation: CytoSorbents, Inc to Present at the BIO International Convention and the In3 East Conference

^{Published on 2009-05-15 06:29:08, Last Modified on 2009-11-02 12:12:12 - Market Wire}
 

MONMOUTH JUNCTION, NJ--(Marketwire - May 15, 2009) - CytoSorbents, Inc, and its parent MedaSorb Technologies Corporation (OTCBB: [ MSBT ]), a clinical trial stage medical device company evaluating CytoSorb™ -- a novel blood purification device for the treatment of severe sepsis, announced that Phillip Chan, MD, PhD, Chief Executive Officer, will present at the BIO International Convention at the Georgia World Congress Center in Atlanta, GA on Tuesday, May 19, 2009. CytoSorbents' presentation is scheduled to begin at 4PM EDT in Room 314. CytoSorbents was one of a select group of companies chosen to make a presentation. The Biotechnology Industry Organization (BIO) represents more than 1,200 biotechnology companies and related organizations from the United States and more than 30 other countries. The conference is the largest biotechnology event in the world, attracting in excess of 20,000 attendees each year from 68 countries. ([ http://convention.bio.org ])

CytoSorbents also announced it will present at the upcoming In3 East medical device conference at the Westin Copley Place Hotel in Boston, MA on Wednesday, June 24, 2009, hosted by Medtech Insight and Windhover Information Inc. Dr. Chan is scheduled to present at 2:10PM EDT. The In3 conference is the largest East Coast strategic partnership and investment conference for medical device companies. MedTech Insight and Windhover, also known as Elsevier Business Intelligence, are subsidiaries of Elsevier, the world's leading publisher of science, technical and health information. ([ http://www.windhover.com/mti/template.asp?page=in3_east09&eventID=16 ])

Copies of the presentations and an investor package are available upon request.

About CytoSorbents and CytoSorb™

CytoSorbents, Inc, with its parent MedaSorb Technologies Corporation, is in clinical trials to treat severe sepsis, often called "overwhelming infection", with a novel blood purification device called CytoSorb™. Severe sepsis is typically caused by bacterial infections like pneumonia, or viral infections like influenza (including virulent avian and swine influenza strains). It afflicts an estimated 18 million people worldwide each year. In countries practicing modern medicine, it still kills one in every three, making it a leading medical cause of death despite the best treatment. In the U.S., more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Much of the organ failure and mortality in severe sepsis is caused by the abnormal massive production of cytokines by the immune system, often called "cytokine storm." CytoSorb™ is a patented highly porous polymer resin that acts as a cytokine filter and was designed to reduce potentially fatal cytokine storm. As blood is pumped through a cartridge of these blood compatible beads using standard dialysis equipment, cytokines and other toxins are captured by the beads and removed from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb™ device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. CytoSorb™ is one of a number of different resins designed for different medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, drug detoxification and others.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on April 10, 2009, which is available at [ http://www.sec.gov ].